Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 12/20 | 0.53 |
| ▸ | MASP2 | O00187 | 1/20 | 0.53 |
| ▸ | PLAU | P00749 | 1/20 | 0.53 |
| ▸ | HPN | P05981 | 1/20 | 0.53 |
| ▸ | TMPRSS6 | Q8IU80 | 8/20 | 0.51 |
| ▸ | ST14 | Q9Y5Y6 | 1/20 | 0.46 |
| ▸ | F10 | P00742 | 3/20 | 0.45 |
| ▸ | PLG | P00747 | 1/20 | 0.45 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.45 |
| ▸ | PROC | P04070 | 1/20 | 0.45 |
| ▸ | F7 | P08709 | 4/20 | 0.45 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.45 |
| ▸ | F3 | P13726 | 1/20 | 0.44 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8291002 | 0.89 | F10 (0.56) | F2MASP2PLAUHPNTMPRSS6 | |
| SCHEMBL8291001 | 0.89 | F10 (0.56) | F2MASP2PLAUHPNTMPRSS6 | |
| SCHEMBL8289986 | 0.86 | F10 (0.55) | F2TMPRSS6F10PLGKLKB1 | |
| SCHEMBL8290754 | 0.86 | F2 (0.51) | F2MASP2PLAUHPNTMPRSS6 | |
| SCHEMBL8290737 | 0.86 | F10 (0.53) | F2TMPRSS6F10PLGKLKB1 | |
| SCHEMBL8289990 | 0.86 | F10 (0.53) | F2TMPRSS6F10PLGKLKB1 | |
| SCHEMBL12156535 | 0.86 | F2 (0.55) | F2MASP2PLAUHPNTMPRSS6 | |
| SCHEMBL12514173 | 0.86 | TMPRSS6 (0.48) | F2TMPRSS6ST14F10PROC | |
| SCHEMBL8290838 | 0.85 | F10 (0.53) | F2F10PLGKLKB1PROC | |
| SCHEMBL12156520 | 0.85 | F2 (0.54) | F2MASP2PLAUHPNTMPRSS6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9090658-B2 | Base-substituted benzylamine analogs for use as coagulation factor Xa inhibitors, the production and use thereof | THE MEDICINES COMPANY (LEIPZIG) GMBH (DE) | 2015-07-28 | — | — | US | disclosed |
| EP-1664089-B1 | BASE-SUBSTITUTED BENZYLAMINE ANALOGS FOR USE AS COAGULATION FACTOR XA INHIBITORS, THE PRODUCTION AND USE THEREOF | MEDICINES CO LEIPZIG GMBH (DE) | 2011-11-16 | — | — | EP | disclosed |
| EP-2292640-A2 | Base-substituted benzylamine analogs for use as coagulation factor Xa inhibitors, the production and use thereof | The Medicines Company (Leipzig) GmbH (DE) | 2011-03-09 | — | — | EP | disclosed |
| US-20070066539-A1 | Base-substituted benzylamine analogs for use as coagulation factor xa inhibitors, the production and use thereof | THE MEDICINES COMPANY (LEIPZIG) GMBH (DE) | 2007-03-22 | — | — | US | disclosed |
| WO-2005026198-A1 | BASE-SUBSTITUTED BENZYLAMINE ANALOGS FOR USE AS COAGULATION FACTOR XA INHIBITORS, THE PRODUCTION AND USE THEREOF | CURACYTE CHEMISTRY GMBH (DE) | 2005-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070066539-A1 | Base-substituted benzylamine analogs for use as coagulation factor xa inhibitors, the production and use thereof | F12, F2, F11 | F2 2/4885MASP2 624/4885PLAU 91/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.